We are neuroscience innovators.
We aim to identify, acquire, and develop a collection of high-potential technologies addressing a broad range of neurological and psychiatric disorders and advance them through approval and commercialization. Our decisions to advance projects are based on fundamental analyses of the science, clinical data, regulatory path, commercial viability, and, above all else: our ability to serve patients and caregivers.
As a Blackstone Life Sciences portfolio company, Neurvati is powered by best-in-class expertise, relentless passion, and deep resources to optimize the development of neuroscience therapeutics. We engage hand-picked strategic partners to broaden our reach while aligning ourselves with patient communities to enhance the development of treatments capable of transforming the lives of patients.
Company Details
- Employees
- 32
- Address
- Grin-Related Neurodevelopmental Disorder (Grin-Ndd) At The 16th European Pediatric Neurology Society (Epns) Congress In Munich. Dr. Sameer Zuberi Will Present The Design Of Our Upcoming Global Phase 3 Trial Of Radiprodil
- Industry
- Biotechnology
- Website
- https://neurvati.com/
- Keywords
- New York.
Neurvati Neurosciences Questions
Neurvati Neurosciences's website is https://neurvati.com/
Neurvati Neurosciences's LinkedIn profile is https://www.linkedin.com/company/neurvati-neurosciences
Neurvati Neurosciences has
32 employees.
View email and phone details for 32
employees at Neurvati Neurosciences.
Neurvati Neurosciences's industry is
Biotechnology
Neurvati Neurosciences's top competitors are
Wave Life Sciences,
Avidity Biosciences, Inc.,
Blackstone,
Stoke Therapeutics,
Click Therapeutics, Inc.,
Grin Therapeutics, Inc.,
Alnylam Pharmaceuticals,
Voyager Therapeutics, Inc.,
Nimbus Therapeutics,
Ovid Therapeutics.
Neurvati Neurosciences's categories are Biotechnology
